Background: We previously validated a 23-gene PCR-based gene expression score (GES) for detection of obstructive coronary artery disease (CAD) (>50% by quantitative coronary angiography). Whether GES is associated with 3-dimensional, quantitative measurements on CTA, using a method we previously validated and published against radiofrequency backscatter intravascular ultrasound (IVUS/VH), is unknown.
Methods:
In the prospective, multi-center COMPASS study, 327 patients (mean age 55; 51% male) had GES measurements (CorusCAD; CardioDX) and CTA, quantitatively analyzed by a core lab using previously validated and published methods. Percent diameter and area stenosis (%DS, %AS) and percent atheroma volume (PAV) in each segment, and volume of calcified plaque (CAP; >150 HU), high-density non-calcified plaque (HD-NCP; 30-150 HU) and lowdensity non-calcified plaque (LD-NCP; -100 to 30 HU) in segments >2 mm were measured. Linear regression was used to assess relationship between GES and plaque/stenosis.
Results:
Obstructive CAD (%DS>50%) was seen in 39 pts (12%). %DS, %AS, PAV, CAP and NCP were significantly correlated to GES ( Figure) . In multivariable analysis including NCP and CAP, only NCP remained significant for GES.
Conclusions:
In the low-risk population of COMPASS, increasing GES was associated with worse stenosis and more plaque; non-calcified plaque was the most important determinant of this largely inflammatory peripheral gene expression pattern.
Figure Legend. Quantitative CT-based stenosis and plaque measurements (left). Green: lumen; yellow: calcified plaque; blue: high-density non-calcified plaque; red: low-density non-calcified plaque. Correlation between CT-parameters and GES shown in the Table. Reference: Voros S, Thomas G, Lansky A, et al. A previously validated, peripheral blood gene expression score is mostly determined by non-calcified plaque and luminal stenosis as assessed by quantitative, 3-dimensional measurements by CT angiography in the multi-center, prospective COMPASS study. J Am Coll Cardiol. 2012;59:E1370.
Abstract Highlights:
• The COMPASS Trial is a prospective multi-center validation study designed to assess a blood-based gene expression test (Corus CAD) for the detection of obstructive CAD in non-diabetic symptomatic patients referred for MPI.
(Results of the COMPASS study were presented at the AHA Scientific Sessions 2011 conference.) • In this subset analysis, 327 patients in the COMPASS Trial received both CT Angiography and the gene expression score. There was a correlation between increasing gene expression score with increased % coronary stenosis and plaque volume.
